<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278187</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453542</org_study_id>
    <secondary_id>UCLA-0504066-01</secondary_id>
    <secondary_id>PDL-M200-1206</secondary_id>
    <nct_id>NCT00278187</nct_id>
  </id_info>
  <brief_title>Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Open-Label Study of Volociximab (M200) in Combination With Erlotinib (Tarceva™) in Previously Treated Patients With Locally Advanced (Stage IIIb) or Metastatic (Stage IV) Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as volociximab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Volociximab may also stop the&#xD;
      growth of non-small cell lung cancer by blocking blood flow to the tumor. Erlotinib may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving&#xD;
      volociximab together with erlotinib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving volociximab together with erlotinib&#xD;
      works in treating patients with stage III or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the response rate in patients with locally advanced (stage IIIB) or metastatic&#xD;
           (stage IV) non-small cell lung cancer treated with volociximab and erlotinib&#xD;
           hydrochloride.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the time to disease progression and duration of response in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Evaluate the safety of this drug regimen in these patients.&#xD;
&#xD;
        -  Evaluate the pharmacokinetics this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive volociximab IV over 30 minutes once every 2 weeks and oral erlotinib&#xD;
      hydrochloride daily for 52 weeks in the absence of unacceptable toxicity or disease&#xD;
      progression.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 and 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with confirmed tumor response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
  </secondary_outcome>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>volociximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced (stage IIIB) or metastatic&#xD;
             (stage IV) non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Failed ≥ 1 prior chemotherapy regimen OR refused first-line therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No active and untreated CNS tumor or metastasis&#xD;
&#xD;
               -  Previously treated CNS tumor(s) allowed if CT scan or MRI shows clear-cut&#xD;
                  response or resolution of the original lesion(s)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  WBC ≥ 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3 (growth factor independent)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if patient has liver&#xD;
             metastases)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  PT/PTT normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective (double barrier or abstinence) contraception&#xD;
&#xD;
          -  No uncontrolled seizure disorder or active neurological disease&#xD;
&#xD;
          -  No thromboembolic events (i.e., stroke or deep vein thrombosis) within the past year&#xD;
&#xD;
          -  No clinically significant medical condition that would complicate compliance with&#xD;
             study treatment or be exacerbated by bleeding, including but not limited to:&#xD;
&#xD;
               -  Known bleeding disorders, such as coagulation defects and thrombasthenias&#xD;
&#xD;
               -  Active gastric or duodenal ulcer&#xD;
&#xD;
               -  History of gastrointestinal (GI) bleeding requiring transfusion within the past&#xD;
                  year&#xD;
&#xD;
               -  History of tumor bleeding&#xD;
&#xD;
               -  History of significant hemoptysis requiring intervention (i.e., transfusion,&#xD;
                  laser therapy, surgical treatment, or radiation) within the past year&#xD;
&#xD;
          -  No known active infections requiring IV antibiotics, antivirals, or antifungals (e.g.,&#xD;
             HIV, hepatitis B, or hepatitis C infection)&#xD;
&#xD;
          -  No unstable cardiac disease, including any of the following:&#xD;
&#xD;
               -  Poorly controlled angina&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Arrhythmias&#xD;
&#xD;
               -  Myocardial infarction within the past year&#xD;
&#xD;
               -  Acute ischemia by ECG&#xD;
&#xD;
               -  Untreated significant conduction abnormality&#xD;
&#xD;
                    -  Bifascicular block (defined as left anterior hemiblock in the presence of&#xD;
                       right bundle branch block)&#xD;
&#xD;
                    -  Second- or third-degree atrioventricular block&#xD;
&#xD;
          -  No asthma or oxygen-dependent chronic pulmonary disease&#xD;
&#xD;
          -  No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past&#xD;
             year&#xD;
&#xD;
          -  No peripheral vascular disease requiring surgery within the past year&#xD;
&#xD;
          -  No clinically significant or unstable medical condition, including, but not limited&#xD;
             to, any of the following:&#xD;
&#xD;
               -  Diabetes mellitus requiring insulin&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Uncontrolled or symptomatic orthostatic hypertension&#xD;
&#xD;
          -  No serious psychiatric illness, active alcoholism, or drug addiction that may preclude&#xD;
             study treatment&#xD;
&#xD;
          -  No condition that, in the investigator's opinion, would make the patient unsuitable&#xD;
             for study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior immunotherapy, including monoclonal antibodies, or vaccine therapy allowed&#xD;
&#xD;
          -  No systemic biologic, immunotherapy, or radiation therapy within the past 4 weeks&#xD;
&#xD;
               -  Local radiotherapy to a single site of bone metastasis within the past 2 weeks&#xD;
                  allowed provided patient has recovered from any side effects&#xD;
&#xD;
          -  No prior volociximab, epidermal growth factor receptor (EGFR) tyrosine kinase&#xD;
             inhibitors, or inhibitors of α5β1 integrin (antibodies or small molecules)&#xD;
&#xD;
          -  No known hypersensitivity to murine proteins or chimeric antibodies or other&#xD;
             components of study drugs&#xD;
&#xD;
          -  No other investigational drug within the past 4 weeks or 5 half-lives (whichever is&#xD;
             longer)&#xD;
&#xD;
          -  No monoclonal antibody therapy within the past 4 weeks or 5 half-lives (whichever is&#xD;
             longer)&#xD;
&#xD;
          -  No major surgery (e.g., thoracotomy) within 4 weeks prior to study entry&#xD;
&#xD;
          -  No minor surgery (e.g., central venous line placement) within 1 week prior to study&#xD;
             entry&#xD;
&#xD;
          -  No sargramostim (GM-CSF) or filgrastim (G-CSF) within the past 7 days&#xD;
&#xD;
          -  No prior bone marrow or stem cell transplantation&#xD;
&#xD;
          -  No concurrent chronic medications that would interfere with study drug assessment&#xD;
             including, but not limited to:&#xD;
&#xD;
               -  High-dose glucocorticoids (prednisone ≥ 20 mg/day or equivalent)&#xD;
&#xD;
               -  Chronic nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
                    -  Infrequent or as occasion requires use of NSAIDs allowed&#xD;
&#xD;
          -  No concurrent high-dose aspirin (&gt; 81 mg/day), high-dose warfarin, or heparin&#xD;
&#xD;
               -  Aspirin ≤ 81 mg/day, low-dose warfarin (1 mg/day), or low-dose heparin for&#xD;
                  IV-catheter patency allowed&#xD;
&#xD;
          -  No concurrent chemotherapy, therapeutic radiation, or anticancer hormonal therapy&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No other concurrent potentially antiangiogenic therapy (e.g., cyclo-oxygenase-2&#xD;
             inhibitors, thalidomide, or tretinoin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Figlin, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Volociximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

